Eurartesim(R) - dihydroartemisinin piperaquine (DHA-PQP) - the first artemisinin combination therapy (ACT) has been approved by the European Medicines Agency (EMA) for the treatment of uncomplicated malaria. Eurartesim was developed collaboratively by Sigma Tau Group, Italy, and the not-for-profit research foundation Medicines for Malaria Venture (MMV).
Eurartesim is now ready for delivery to Cambodia, the first malaria endemic country to place an order for the newly approved treatment. Cambodia prioritized the use of DHA-PQP as a first line drug and was awaiting EMA approval to allow procurement of this product using international donor funds.